KPV Research Overview: α-MSH Fragment and Cellular Signaling

KPV is the tripeptide lysine-proline-valine (Lys-Pro-Val), corresponding to residues 11–13 at the C-terminus of alpha-melanocyte-stimulating hormone (α-MSH). This compact fragment is studied as a research tool for separating C-terminal fragment activity from the broader signaling profile of the 13-residue parent peptide.

This overview focuses on what published experimental work measures: cellular anti-inflammatory-signaling and immune-modulation endpoints. It does not infer outcomes beyond the cell, tissue, or model system being examined.

Structural relationship to α-MSH

α-MSH contains 13 amino-acid residues. KPV comprises its final three residues and does not contain the central His-Phe-Arg-Trp melanocortin pharmacophore. That structural difference is important when interpreting assays: observations made with KPV should not be treated as interchangeable with findings from the complete α-MSH sequence.

The short sequence also affects experimental design. Cell type, peptide concentration, incubation period, transporter expression, media conditions, and assay selection can all change the resulting signal. Researchers should therefore compare KPV data only within clearly defined controls.

Cellular signaling endpoints

Published KPV studies commonly examine NF-κB activation and nuclear translocation, together with downstream cytokine-expression readouts such as TNF-α, IL-1β, IL-6, and IL-8. These are pathway-level measurements used to evaluate how a model responds under specified experimental conditions.

Some work reports intracellular activity alongside melanocortin-receptor-related observations. The relative contribution of receptor-dependent and receptor-independent processes remains dependent on the cell system and methods used. Claims of one universal mechanism would exceed the available evidence.

Peptide-transporter research

As a tripeptide, KPV can be evaluated in systems that express di- and tripeptide transporters such as PepT1. Transporter abundance and localization vary between experimental preparations, so uptake findings should not be generalized across unrelated cell types. Transporter inhibition, matched controls, and direct intracellular measurements help distinguish uptake from downstream signaling.

Cytokine-expression and immune-modulation models

KPV research also measures changes in transcription, protein abundance, and secretion of signaling mediators. These endpoints can clarify sequence-response relationships and timing, but they are not interchangeable. A change in transcript abundance does not necessarily establish the same change in protein secretion or pathway activity.

Useful designs report baseline conditions, positive and negative controls, concentration ranges, exposure windows, replicate counts, and the method used to normalize each readout. This detail is essential when comparing results across laboratories.

Interpreting the research

Most KPV evidence comes from cellular and model-system experiments. Differences in species, tissue source, assay conditions, formulation, and analytical method limit direct comparison. Experimental findings should remain tied to the model in which they were generated.

For the current 10 mg vial offer, specifications, documentation context, and the separate 8 mg analytical report are available on the KPV research material page.

Research limitations

KPV's short sequence does not remove the need for identity confirmation, purity assessment, matched controls, and pre-specified endpoints. Studies should also distinguish the catalog purity specification from an individual report result and should not assume that documentation for one sample size represents another offer.

Research Use Only. This content is intended for laboratory research and analytical reference only. Not for human consumption.

Running the numbers for a protocol? Use the Peptide Concentration Calculator to convert mg, mL, and syringe units.